首页> 外文期刊>Hepatitis Monthly >Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis
【24h】

Liver Fibrosis is Associated with NAFLD Activity Score in Chronic Hepatitis B Patients with Liver Steatosis

机译:慢性乙型肝炎肝脂肪变性患者肝纤维化与NAFLD活性评分相关

获取原文
       

摘要

Background: Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are two leading hepatic diseases that cause severe public health problems. The relationship between the severity of NAFLD and liver fibrosis in CHB patients remains controversial. Objectives: This study aimed at further clarifying the association between them. Methods: A total of 272 CHB patients and 31 NAFLD patients without CHB, who underwent liver biopsies and routine blood tests were included. The NAFLD activity scores (NAS) for NAFLD patients and the METAVIR scoring system for all the patients were used to evaluate the liver pathology. The associations between steatosis or NAS score and liver fibrosis were statistically analyzed. Results: METAVIR F0-4 was identified in 10.0%, 30.5%, 36.0%, 13.2%, and 10.3% of all the CHB patients, respectively. The prevalence of hepatic steatosis in CHB patients was 39.7% (n = 108). Among them, 26.9% (n = 29) of patients had NAS ≥ 5. The severity of fibrosis was not related to the degree of steatosis nor NAS score (P 0.05) in NAFLD patients without CHB. Similarly, the results suggested that there was no significant difference in the severity of liver fibrosis in CHB patients with varying degrees of steatosis (P 0.05). However, the severity of liver fibrosis increased with NAS score (P = 0.004) in CHB patients with NAFLD. Conclusions: The severity of liver fibrosis in CHB patients was associated with NAS score, yet not with fat content.
机译:背景:慢性乙型肝炎(CHB)和非酒精性脂肪肝疾病(NAFLD)是引起严重的公共卫生问题的两种主要的肝病。 CHB患者NAFLD严重程度与肝纤维化之间的关系仍存在争议。目的:本研究旨在进一步阐明它们之间的关联。方法:纳入272例CHB患者和31例无CHB的NAFLD患者,他们均接受了肝活检和常规血液检查。将NAFLD患者的NAFLD活动评分(NAS)和所有患者的METAVIR评分系统用于评估肝脏病理。统计分析脂肪变性或NAS评分与肝纤维化之间的关系。结果:在所有CHB患者中,METAVIR F0-4的检出率分别为10.0%,30.5%,36.0%,13.2%和10.3%。 CHB患者肝脂肪变性的患病率为39.7%(n = 108)。其中,26.9%(n = 29)的患者的NAS≥5。在无CHB的NAFLD患者中,纤维化的严重程度与脂肪变性程度和NAS评分无关(P> 0.05)。同样,结果表明,在不同程度的脂肪变性的CHB患者中,肝纤维化的严重程度也没有显着差异(P> 0.05)。但是,在NAFLD的CHB患者中,肝纤维化的严重程度随NAS评分的升高而增加(P = 0.004)。结论:CHB患者肝纤维化的严重程度与NAS评分有关,而与脂肪含量无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号